Diversified Healthcare Trust (DHC) has been rated a 'Buy' due to improved fundamentals and a stronger balance sheet despite recent share price gains. In Q2 2026, its SHOP segment's net operating income rose 37.2% year-over-year, with normalized funds from operations (FFO) surging 109.4% to $0.16 per share. The company has successfully reduced leverage, with net debt to adjusted EBITDAre falling to 7.1x, no major debt maturities until 2028, and $270 million in liquidity. DHC prioritizes balance sheet strength over dividends, supported by SHOP segment growth and a supply-demand imbalance, making it an attractive investment opportunity.
Micron has committed to investing $10 billion over the next decade to build a new research laboratory, with construction starting in 2027. This significant investment highlights Micron's focus on advancing technology and innovation in its field. The ...
Gen Digital is currently valued at less than 10 times its expected earnings for fiscal 2027, despite showing accelerating growth and strong cash flow. Its Cyber Safety segment is stabilizing with high profit margins, while its MoneyLion division is g...
U.S. stocks closed higher on Friday with the Dow Jones rising 518 points (1%) and the S&P 500 and Nasdaq up 0.4%, but weekly losses ended three-week winning streaks amid Treasury market volatility. Treasury Secretary Scott Bessent's bond buyback expa...
A trading expert forecasts SpaceX stock to trade near $300 in early 2027, following a breakout above a major resistance zone that ended its post-IPO consolidation phase. After its June 2026 IPO, SpaceX surged to $225 before correcting near $100, then...
At The International 2026 Dota 2 tournament, 18-year-old Russian carry player Alan “Satanic” Gallyamov is delivering exceptional performances, including a 7/0/18 KDA and 71% kill participation in a recent match. He leads all players in key metrics li...
